A first-in-human study of the anti-inflammatory profibrinolytic TMS-007, an SMTP family triprenyl phenol.
Takashi MoritoyoNaoko NishimuraKeiko HasegawaShinya IshiiKenji KiriharaMunenori TakataAkiko Kishi SvenssonYumi Umeda-KameyamaShuichi KawarasakiRyoko IharaChie SakanakaYurie WakabayashiKuniyasu NiizumaTeiji TominagaTsutomu YamazakiKeiji HasumiPublished in: British journal of clinical pharmacology (2022)
TMS-007 is generally well tolerated and exhibits favorable pharmacokinetic profiles that warrant further clinical development.